Surgical management and clinical outcomes of cerebellar liponeurocytomas—a report of seven cases and a pooled analysis of individual patient data

2022 ◽  
Author(s):  
Pengcheng Zuo ◽  
Tao Sun ◽  
Guocan Gu ◽  
Xiaoou Li ◽  
Zhuang Jiang ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Surgical Management ◽  
Individual Patient Data ◽  
Pooled Analysis ◽  
Patient Data

Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data

2020 ◽  
Vol 15 (16) ◽  
pp. 1451-1457 ◽  
Author(s):  
Salvatore Cassese ◽  
Yuki Katagiri ◽  
Robert A. Byrne ◽  
Salvatore Brugaletta ◽  
Fernando Alfonso ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Individual Patient Data ◽  
Pooled Analysis ◽  
Patient Data

scholarly journals Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data

2019 ◽  
Vol 4 (11) ◽  
pp. e553-e564 ◽  
Author(s):  
Dongshan Zhu ◽  
Hsin-Fang Chung ◽  
Annette J Dobson ◽  
Nirmala Pandeya ◽  
Graham G Giles ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Individual Patient Data ◽  
Pooled Analysis ◽  
Patient Data ◽  
Natural Menopause ◽  
Incident Cardiovascular Disease

scholarly journals Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate

2021 ◽  
Vol 14 ◽  
pp. 175628642097591
Author(s):  
Thomas F. Scott ◽  
Ray Su ◽  
Kuangnan Xiong ◽  
Arman Altincatal ◽  
Carmen Castrillo-Viguera ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Propensity Score ◽  
Clinical Outcomes ◽  
Glatiramer Acetate ◽  
Therapeutic Efficacy ◽  
Individual Patient Data ◽  
Patient Data ◽  
Phase Iii ◽  
Lower Probability ◽  
Phase Iii Clinical Trials

Background: Peginterferon beta-1a and glatiramer acetate (GA) are approved first-line therapies for the treatment of relapsing forms of multiple sclerosis, but their therapeutic efficacy has not been compared directly. Methods: Clinical outcomes at 2 years, including no evidence of disease activity (NEDA), for patients receiving peginterferon beta-1a 125 mcg every 2 weeks (Q2W) or GA 20 mg/ml once daily (QD) were compared by propensity score matching analysis using individual patient data from ADVANCE and CONFIRM phase III clinical trials. In addition, clinical outcomes at 1–3 years for patients receiving peginterferon beta-1a Q2W or GA 40 mg/ml three times a week (TIW) were evaluated using a matching-adjusted comparison analysis of individual patient data from ADVANCE and the ADVANCE extension study, ATTAIN, and aggregate patient data from the phase III GALA and the GALA extension studies. Results: Propensity-score-matched peginterferon beta-1a patients ( n = 336) had a significantly lower annualized relapse rate [ARR (0.204 versus 0.282); rate ratio = 0.724; p = 0.045], a significantly lower probability of 12-week confirmed disability worsening (10.0% versus 14.6%; hazard ratio = 0.625; p = 0.048), and a significantly higher rate of NEDA (20.3% versus 11.5%; p = 0.047) compared with GA 20 mg/ml QD patients after 2 years of treatment. Matching-adjusted peginterferon beta-1a patients (effective n = 276) demonstrated a similar ARR at 1 year (0.278 versus 0.318; p = 0.375) and significantly lower ARR at 2 years (0.0901 versus 0.203; p = 0.032) and 3 years (0.109 versus 0.209; p = 0.047) compared with GA 40 mg/ml TIW patients ( n = 834). Conclusion: Results from separate matching comparisons of phase III clinical trials and extension studies suggest that peginterferon beta-1a 125 mcg Q2W may provide better clinical outcomes than GA (20 mg/ml QD or 40 mg/ml TIW).

scholarly journals Treatment of renal angiomyolipoma: pooled analysis of individual patient data

BMC Urology ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Teele Kuusk ◽  
Fausto Biancari ◽  
Brian Lane ◽  
Conrad Tobert ◽  
Steven Campbell ◽  
...  
Keyword(s):  
Individual Patient Data ◽  
Pooled Analysis ◽  
Patient Data ◽  
Renal Angiomyolipoma

scholarly journals Association of RASSF1A, DCR2, and CASP8 Methylation with Survival in Neuroblastoma: A Pooled Analysis Using Reconstructed Individual Patient Data

2020 ◽  
Vol 2020 ◽  
pp. 1-12
Author(s):  
Waleed M. Hassan ◽  
Mohamed S. Bakry ◽  
Timo Siepmann ◽  
Ben Illigens
Keyword(s):  
Overall Survival ◽  
Individual Patient Data ◽  
Wide Spectrum ◽  
Pooled Analysis ◽  
Patient Data ◽  
Epigenetic Alterations ◽  
Full Data ◽  
Data Set ◽  
Kaplan Meier ◽  
Registration Number

Neuroblastoma (NB) is a heterogeneous tumor affecting children. It shows a wide spectrum of clinical outcomes; therefore, development of risk stratification is critical to provide optimum treatment. Since epigenetic alterations such as DNA methylation have emerged as an important feature of both development and progression in NB, in this study, we aimed to quantify the effect of methylation of three distinct genes (RASSF1A, DCR2, and CASP8) on overall survival in NB patients. We performed a systematic review using PubMed, Embase, and Cochrane libraries. Individual patient data was retrieved from extracted Kaplan–Meier curves. Data from studies was then merged, and analysis was done on the full data set. Seven studies met the inclusion criteria. Methylation of the three genes had worse overall survival than the unmethylated arms. Five-year survival for the methylated arm of RASSF1A, DCR2, and CASP8 was 63.19% (95% CI 56.55-70.60), 57.78% (95% CI 47.63-70.08), and 56.39% (95% CI 49.53-64.19), respectively, while for the unmethylated arm, it was 93.10% (95% CI 87.40–99.1), 84.84% (95% CI 80.04-89.92), and 83.68% (95% CI 80.28-87.22), respectively. In conclusion, our results indicate that in NB patients, RASSF1A, DCR2, and CASP8 methylation is associated with poor prognosis. Large prospective studies will be necessary to confirm definitive correlation between methylation of these genes and survival taking into account all other known risk factors. (PROSPERO registration number CRD42017082264).

scholarly journals TCT-67 Predictors and Outcomes After Stent Failure Is Treated With Either CABG or PCI: An Individual Patient-Data Pooled Analysis From 32,880 Patients

2019 ◽  
Vol 74 (13) ◽  
pp. B67
Author(s):  
Zhaoyang Chen ◽  
Akiko Maehara ◽  
Aaron Crowley ◽  
Gary Mintz ◽  
Pieter Smits ◽  
...  
Keyword(s):  
Individual Patient Data ◽  
Pooled Analysis ◽  
Patient Data
Sign in / Sign up

Export Citation Format

Share Document